Poxel (POXEL.PA)

Executive Summary

Poxel is a clinical-stage biopharmaceutical company headquartered in Lyon, France, that focuses on developing innovative treatments for chronic metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare disorders. The company's lead pipeline includes PXL770, a direct AMP kinase activator targeting NASH, and Imeglimin, a first-in-class oral agent for type 2 diabetes that has been partnered in Japan and is undergoing regulatory review in other regions. Despite a strong scientific rationale, Poxel has faced clinical setbacks, including the withdrawal of a Phase 2 trial for adrenomyeloneuropathy. The company's current valuation remains modest, reflecting uncertainty around pipeline execution and the need for near-term catalysts to demonstrate progress. Poxel is actively seeking partnerships to advance its programs and secure non-dilutive funding.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 data readout for PXL770 in NASH30% success
• Q3 2026Regulatory update or partnership for Imeglimin in Europe/China40% success
• Q4 2026Financing or licensing deal to extend cash runway50% success